Table 1 Baseline demographic and clinical characteristics
Variable | SC placebo + oral indomethacin (n= 75) | SC rilonacept + oral indomethacin (n= 74) | SC rilonacept + oral placebo (n= 73) |
|---|---|---|---|
Age, years, mean (SD) | 51.3 (10.9) | 48.6 (10.0) | 51.0 (10.8) |
Gender, n (%) | Â | Â | Â |
   Male | 71 (94.7) | 71 (95.9) | 67 (91.8) |
   Female | 4 (5.3) | 3 (4.1) | 6 (8.2) |
Race, n (%) | Â | Â | Â |
   White | 54 (72.0) | 54 (73.0) | 60 (82.2) |
   Black or African American | 15 (20.0) | 15 (20.3) | 11 (15.1) |
   Asian | 5 (6.7) | 2 (2.7) | 2 (2.7) |
   Other | 1 (1.3) | 3 (4.1) | 0 |
BMI, kg/m2, mean (SD) | 32.1 (6.3) | 33.5 (7.5) | 33.7 (6.7) |
Pain severity, mean (SD) | Â | Â | Â |
   Likert scale (0 to 4) | 2.6 (0.7) | 2.7 (0.7) | 2.6 (0.7) |
   Numerical rating scale (0 to 10) | 6.8 (2.2) | 6.8 (2.0) | 6.5 (2.3) |
Duration of disease, years, mean (SD) | 8.8 (6.7) | 11.0 (7.9) | 10.2 (9.9) |
Prior number of gout flares per year, mean (SD) | 4.8 (5.19) | 5.5 (5.26) | 5.2 (4.76) |
Duration of a typical gout flare, days, mean (SD) | 5.8 (3.6) | 7.1 (4.2) | 6.8 (7.3) |
Tophi present, n (%) | 10 (13.3) | 12 (16.2) | 13 (17.8) |
Serum uric acid, mg/dL, mean (SD) | 7.9 (1.9) | 8.2 (2.1) | 8.3 (1.7) |
Prior medication use, n (%) | Â | Â | Â |
   Urate-lowering therapy | 28 (37.3) | 34 (45.9) | 27 (37.0) |
   Analgesics (paracetamol or acetylsalicylic acid) | 2 (2.7) | 9 (12.2) | 7 (9.6) |